{
    "clinical_study": {
        "@rank": "151500", 
        "acronym": "AdaProQuo", 
        "arm_group": {
            "arm_group_label": "moderate to severe Ulcerative Colitis", 
            "description": "Patients with moderate to severe Ulcerative Colitis who have not responded despite a full and adequate course of therapy with a corticosteroid and an immunosuppressant (Azathioprin (AZA)/ 6-Mercaptopurin (6-MP)); or who are intolerant to or have medical contraindications for such therapies and are hence prescribed adalimumab for the treatment of moderate to severely active UC"
        }, 
        "brief_summary": {
            "textblock": "The objectives of this study are to explore the effect of adalimumab on the fecal\n      Calprotectin level of UC (Ulcerative Colitis) patients and the correlation with their\n      general well-being (QoL), work ability and disease activity."
        }, 
        "brief_title": "Influence of ADA (Adalimumab) on Fecal Calprotectin, QoL (Quality of Life) and Workability of Patients Suffering From Ulcerative Colitis", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Moderate to Severe Ulcerative Colitis", 
        "condition_browse": {
            "mesh_term": [
                "Colitis", 
                "Colitis, Ulcerative", 
                "Ulcer", 
                "Stress, Psychological"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a non-interventional, observational study in which Humira (adalimumab) is prescribed\n      in the usual manner in accordance with the terms of the local marketing authorization with\n      regards to dose, population and indication. The assignment of the patient to a Humira\n      containing regimen has to be decided in advance and has to be current practice. The\n      prescription of Humira is clearly separated from the decision to include the participant in\n      this study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with moderate to severe Ulcerative Colitis who have not responded despite a\n             full and adequate course of therapy with a corticosteroid and an immunosuppressant\n             (AZA/6-MP); or who are intolerant to or have medical contraindications for such\n             therapies and are hence prescribed adalimumab for the treatment of moderate to\n             severely active UC\n\n          -  Patients which are able to complete patients questionnaires (like WPAI:UC and sIBDQ\n             questionnaire)\n\n          -  Patients must fulfill national and international guidelines for the use of biologic\n             therapies in Ulcerative Colitis [Chest X-ray and IGRA (Interferon-Gamma-Release\n             Assay) or PPD (tuberculin purified protein derivative)-skin test negative for\n             tuberculosis].\n\n          -  Patients who have been prescribed adalimumab in line with the European SmPC (Summary\n             of Product Characteristics)\n\n        Exclusion Criteria:\n\n          -  Previous therapy with TNF-alpha (Tumor necrosis factor alpha) blocker\n\n          -  no signed written authorization to use data\n\n          -  Contraindication to adalimumab therapy according to the Summary of Product\n             Characteristics (SmPC)\n\n          -  Subjects with a history of subtotal colectomy with ileorectostomy or colectomy with\n             ileoanal pouch, Koch pouch, or ileostomy for UC or planned bowel surgery.\n\n          -  Subjects received intravenous (IV) corticosteroids within 14 days of Screening or\n             during the Screening period.\n\n          -  pregnant subjects"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients with moderate to severe Ulcerative Colitis"
            }
        }, 
        "enrollment": {
            "#text": "70", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 18, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02092389", 
            "org_study_id": "P14-323"
        }, 
        "intervention_browse": {
            "mesh_term": "Adalimumab"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Ulcerative Colitis", 
            "TNF (Tumor necrosis factor) alpha Antibody", 
            "Calprotectin", 
            "Adalimumab", 
            "Inflammatory Bowel Syndrome"
        ], 
        "lastchanged_date": "March 18, 2014", 
        "link": {
            "url": "http://www.rxabbvie.com"
        }, 
        "number_of_groups": "1", 
        "official_title": "Influence of ADA on Fecal Calprotectin, QoL and Workability of Patients Suffering From Ulcerative Colitis - AdaProQuo", 
        "overall_contact": {
            "email": "astrid.dworan-timler@abbvie.com", 
            "last_name": "Astrid  Dworan-Timler, MD", 
            "phone": "+43-1-20589-391"
        }, 
        "overall_contact_backup": {
            "email": "marlies.neuhold@abbvie.com", 
            "last_name": "Marlies  Neuhold, MD", 
            "phone": "+43-1-20589-379"
        }, 
        "overall_official": {
            "affiliation": "AbbVie Austria", 
            "last_name": "Astrid  Dworan-Timler, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Austria: Agency for Health and Food Safety", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Calprotectin levels should be measured using Enzyme Linked Immunosorbent Assay (ELISA) and / or a validated quantitative rapid test", 
            "measure": "Change of Percentage of patients with fecal calprotectin level <= 150\u00b5g/g", 
            "safety_issue": "No", 
            "time_frame": "from month 0 to month 12"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02092389"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The short Inflammatory Bowel Disease Questionnaire (sIBDQ) is an 10 item questionnaire which incorporate elements of social, systemic and emotional symptoms, as well as bowel related symptoms into an activity index.", 
                "measure": "Change in patients quality of life measured with the short Inflammatory Bowel Disease Questionnaire (sIBDQ)", 
                "safety_issue": "No", 
                "time_frame": "from Day 0 to month 12"
            }, 
            {
                "description": "The Work Productivity and Activity Impairment (WPAI) questionnaire measures work time missed and work and activity impairment due to a specified health problem during the past 7 days.", 
                "measure": "Change in patients workability measured with the Work Productivity and Activity Impairment (WPAI):UC questionnaire", 
                "safety_issue": "No", 
                "time_frame": "from Day 0 to month 12"
            }, 
            {
                "description": "the correlation of fecal Calprotectin levels in \u00b5g/g measured using ELISA and / or a validated quantitative rapid test", 
                "measure": "Correlation of fecal Calprotectin", 
                "safety_issue": "No", 
                "time_frame": "Up to month 12"
            }, 
            {
                "description": "the correlation of fecal Calprotectin levels in \u00b5g/g ensured using ELISA and / or a validated quantitative rapid test and be stratified by CRP (C Reactive Protein) Levels on day 0.", 
                "measure": "Correlation of fecal Calprotectin stratified by C-reactive protein (CRP) Levels", 
                "safety_issue": "No", 
                "time_frame": "Up to month 12"
            }, 
            {
                "description": "Assessed using partial Mayo score", 
                "measure": "Disease Activity Score (DAS)", 
                "safety_issue": "No", 
                "time_frame": "Up to month 12"
            }, 
            {
                "description": "the correlation disease activity using the partial Mayo Score will be stratified by baseline CRP (C Reactive Protein) Levels on Day 0.", 
                "measure": "Correlation of disease activity stratified to CRP Levels", 
                "safety_issue": "No", 
                "time_frame": "up to month 12"
            }, 
            {
                "description": "the correlation of QoL using the sIBDQ questionnaire will be stratified by baseline CRP (C Reactive Protein) Levels on day 0.", 
                "measure": "Correlation of quality of life stratified to CRP Levels", 
                "safety_issue": "No", 
                "time_frame": "up to month 12"
            }, 
            {
                "description": "the correlation of workability using the WPAI:UC questionnaire will be stratified by baseline CRP (C Reactive Protein) Levels on Day 0.", 
                "measure": "Correlation of workability stratified to CRP Levels", 
                "safety_issue": "No", 
                "time_frame": "up to month 12"
            }
        ], 
        "source": "AbbVie", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AbbVie", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "March 2014"
    }
}